Radioconjugates targeting cd33 in the treatment of breast cancer
US-2026053963-A1 · Feb 26, 2026 · US
This page is not indexed by search engines while we improve data quality.
Seth Sandesh patents
Seth Sandesh is listed as an inventor on 27 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Seth Sandesh |
| Total patents | 27 |
| First publication | Apr 23, 2020 |
| Latest publication | Feb 26, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Radioconjugates targeting CD33 in the treatment of cancers
US-12539340-B2 · Feb 3, 2026 · US
Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
US-2025339571-A1 · Nov 6, 2025 · US
Her3 radioimmunotherapy for the treatment of solid cancers
US-2025205375-A1 · Jun 26, 2025 · US
Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
US-2025121105-A1 · Apr 17, 2025 · US
Methods for treating cd33-positive hematological malignancies
US-2025073274-A1 · Mar 6, 2025 · US
Radioimmunoconjugates targeting grp78 for use in the treatment of cancer
US-2024390532-A1 · Nov 28, 2024 · US
Radioimmunoconjugates targeting calreticulin for use in the treatment of cancer
US-2024226345-A1 · Jul 11, 2024 · US
Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer
US-2024216554-A1 · Jul 4, 2024 · US
Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells
US-2024197931-A1 · Jun 20, 2024 · US
Recent patents
Latest publications not already listed above.
Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
US-2024158528-A1 · May 16, 2024 · US
Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
US-11912780-B2 · Feb 27, 2024 · US
Radioconjugates targeting cd33 in the treatment of cancers
US-2023302167-A1 · Sep 28, 2023 · US
Her3 radioimmunotherapy for the treatment of solid cancers
US-2023248855-A1 · Aug 10, 2023 · US
Combination therapy for treatment of a hematological disease
US-2023132400-A9 · Apr 27, 2023 · US
Radiolabeling of anti-cd45 immunoglobulin and methods of use thereof
US-2022378955-A1 · Dec 1, 2022 · US
Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
US-2022288244-A1 · Sep 15, 2022 · US
Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
US-2022251239-A1 · Aug 11, 2022 · US
Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
US-2022211886-A1 · Jul 7, 2022 · US
Her3 radioimmunotherapy for the treatment of solid cancers
US-2022143228-A1 · May 12, 2022 · US
Antibodies Conjugated With Actinium-225 and Actinium-227, and Related Compositions and Methods
US-2022125962-A1 · Apr 28, 2022 · US
Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody Radioconjugates
US-2022072167-A1 · Mar 10, 2022 · US
Anti-cd45-based lymphodepletion methods and uses thereof in conjction with act-based cancer therapies
US-2021198359-A1 · Jul 1, 2021 · US
Methods for cancer treatment using a radiolabeled anti-cd45 immunoglobulin and adoptive cell therapies
US-2020308280-A1 · Oct 1, 2020 · US
Combination therapy for treatment of a hematological disease
US-2020283539-A1 · Sep 10, 2020 · US
Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
US-2020255520-A1 · Aug 13, 2020 · US
Treatments for a hematological malignancy
US-2020121815-A1 · Apr 23, 2020 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Actinium Pharmaceuticals Inc | 27 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61K51/1096 | 25 |
| A61K51/1027 | 23 |
| A61P35/00 | 23 |
| C07K16/2803 | 17 |
| A61K2039/505 | 15 |